… new users of oral anticoagulants (OACs) since January 2014, 7,576 warfarin users and
14,103 direct oral anticoagulant (DOAC) users were included in this study. AF = atrial fibrillation; …

… Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main cause of
anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this context. On the …

… the use of direct oral anticoagulants (DOACs) in patient with extreme body weight. Thus, the
… in patients with weight >120 Kg, and on the contrary, no restrictions exist for underweight …

… weighing ≥ 120 kg matched to patients weighing < 120 kg and is one of … body of evidence
indicating that direct oral anticoagulants may be well-tolerated and effective anticoagulants in …

… The keywords utilized were ‘non-vitamin K antagonist oral anticoagulants’ or ‘direct oral
anticoagulants’ or ‘dabigatran’ or ‘rivaroxaban’ or ‘apixaban’ or ‘edoxaban’ or ‘warfarin’ and ‘…

… direct oral anticoagulant (DOAC) outcomes (vs. warfarin) in patients with atrial fibrillation (AF)
across body … 4,000 patients with non-valvular atrial fibrillation (NVAF) with BMI of ≥40 kg/m …

… are now the preferred method of anticoagulation in patients with atrial fibrillation. … in patients
with atrial fibrillation taking direct‐acting oral anticoagulants across body mass index (BMI) …

… Direct oral anticoagulants (DOACs) and warfarin are widely used for the prevention of systemic
embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE)…

… –2.115) compared to normal BMI patients. In conclusion, DOACs for atrial fibrillation or VTE
in patients with extreme body weights appear safe and effective when compared to warfarin. …

… of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation and
extreme body weight reinforces recent therapeutics advances in anticoagulation in these patient …